NEET PG NEXT LATEST DRUG DONANENAB:PHARMACOLOGY
🚀 #AlzheimersResearch, #Donanemab, #EliLilly, #MedicalBreakthrough, #BrainHealth, #ClinicalTrials, #HopeForCure, #FightAlzheimers, #MedicalInnovation, #Neurology, #HealthRevolution, #ScienceNews, #SubscribeNow, #NewAlzheimersTreatment, #DonanemabReview, #FDAApproval, #AlzheimersTreatmentUpdates, #AmyloidPlaques, #EarlyAlzheimers, #InnovativeMedicine! 🚀
🔬 What is Donanemab?
Donanemab, also known as N3pG, is an innovative antibody developed by Eli Lilly and Co. It's designed to target and reduce amyloid beta (Aβ) plaques in the brain, potentially slowing the progression of early Alzheimer's disease. 🌟
🧠 How Does It Work?
Donanemab binds to amyloid plaques, clearing them from the brain. These plaques are linked to Alzheimer's progression, disrupting neural communication. With advancements in amyloid imaging, donanemab's ability to reduce both soluble and insoluble plaques offers hope in combating this debilitating disease. 💡
🎥 Clinical Trials Breakdown:
Phase I: Initial trials in the US and Japan with 100 participants showed a 40% reduction in plaques at higher doses, despite some adverse effects.
Phase II (TRAILBLAZER-ALZ): Conducted over 72 weeks with 257 participants, this phase showed promising reductions in plaque levels and improved cognitive function.
Phase III: Extended globally, with results in 2023 showing a 35% slowdown in Alzheimer's progression at 76 weeks! 📉
⚠️ Side Effects & Safety:
Common side effects include infusion reactions (chills, dizziness, rash, fever).
Cases of ARIA-E (cerebral edema) and ARIA-H (cerebral hemorrhages) were noted, mostly asymptomatic.
Anti-drug antibodies were frequent, impacting the drug's effectiveness.
📅 What's Next?
In March 2024, the FDA will review donanemab's efficacy and safety further, bringing us closer to a breakthrough in Alzheimer's treatment! 🌟
🌐 Join the Fight Against Alzheimer's!
Stay updated on donanemab's journey and the latest in Alzheimer's research. Together, we can make a difference! 💪
🔔 Subscribe, Like & Share! 🔔
Don't forget to hit the subscribe button, like this video, and share it with your friends and family. Let's spread the word about this exciting advancement in Alzheimer's treatment! 🌍
#AlzheimersResearch #Donanemab #EliLilly #MedicalBreakthrough #BrainHealth #ClinicalTrials #HopeForCure #FightAlzheimers #MedicalInnovation #Neurology #HealthRevolution #ScienceNews #SubscribeNow
💡 Related Treatments:
Aducanumab (Biogen)
Lecanemab (Biogen and Eisai)
📚 References:
Mintun MA, Lo AC, Duggan Evans C, et al. (May 2021). "Donanemab in Early Alzheimer's Disease". The New England Journal of Medicine.
Sims JR, Zimmer JA, Evans CD, et al. (17 July 2023). "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial". JAMA.
👉 Stay tuned for more updates and breakthroughs in the world of medical science!